Antihyperlipidemic Activity Research Articles

Investigating the Anti-diabetic and Lipid-regulating Properties of Eclipta alba in Alloxan-induced Diabetes

Since the dawn of human civilization, humanity has used herbal medicine for medicinal purposes. Traditional medicine has experienced a substantial surge in popularity in recent years. This research sought to evaluate the antidiabetic effectiveness and lipid profile of Eclipta alba. We evaluated the antidiabetic efficacy using the alloxan-induced diabetic model. The dosages of 800 mg/kg and 1200 mg/kg in groups 5 and 6, respectively, yielded statistically significant findings (p < 0.05) regarding antidiabetic efficacy. The group receiving a 1200 mg/kg dosage had statistically significant outcomes for total cholesterol and LDL, with findings of 196.15 ± 8.91* and 123.77 ± 6.50*, respectively (p < 0.05). However, no groups exhibited statistically significant results for HDL and triglyceride levels, despite a reduction in these parameters in the blood after the administration of the extract. Group 6, with a dosage of 1200 mg/kg, exhibited statistically significant results (p < 0.05) for SGPT and SGOT, with values of 88.71 ± 6.23* and 92.82 ± 7.50*, respectively. In the kidney function test, groups 5 and 6 exhibited statistically significant results (p < 0.05) at doses of 800 and 1200 mg/kg. So ethanolic extract of this plant shows significant antidiabetic and antihyperlipidemic activity and further advanced research on this plant may add alternative medicine to the treatment system.

Characterization and interactions between piperine and ezetimibe in their Anti-hyperlipidemic efficacy using Biopharmaceutics and Pharmacokinetics

BackgroundPiperine, a secondary metabolite, affects the antihyperlipidemic effect of Ezetimibe (EZ). Hyperlipidemia is one of the independent risk factors for cardiovascular disorders such as atherosclerosis. Antihyperlipidemic drugs are essential for reducing cardiovascular events and patient mortality. Our study aimed to improve the solubility of EZ, a lipid-lowering drug that belongs to BCS II and has low solubility. Piperine, a bioenhancer, can increase the bioavailability of other pharmaceuticals without modifying their fundamental characteristics or enhancing their efficacy. The objective of this study was to increase the bioavailability of EZ while also improving its potency and reducing its toxicity by using piperine as a bioenhancer. Therefore, rats were given piperine combined with EZ, and their antihyperlipidemic activity was assessed while fed a high-fat diet.MethodThe in vivo antihyperlipidemic effect of EZ with piperine was assessed at doses of 10 and 5–20 mg/kg b.w. The evaluation was conducted using propylthiouracil-induced and triton X-100-induced hyperlipidemia in rats. Give 400 mg/kg body weight of propylthiouracil along with piperine. Serum levels of total cholesterol (TC) (p < 0.01), triglycerides (TG) (p < 0.01), low-density lipoprotein (LDL) (p < 0.01), and very low-density lipoprotein (VLDL) (p < 0.01) all went up significantly. Additionally, it led to the induction of high-density lipoprotein (HDL) (p < 0.01). Administration of Triton X-100 via intraperitoneal injection at a single dose resulted in an elevation of lipid levels.ResultsLower levels of high-density lipoprotein (LDL), total cholesterol (TC), triglycerides (TG), and very low-density lipoprotein (VLDL) were significantly reduced by EZ at 10 mg/kg b.w. and piperine at 20 mg/kg b.w., respectively (p < 0.01 and p < 0.05). Liver histology studies provided further evidence supporting the present findings. Areas of concentrated periportal lymphocytes and hepatocytes formed a cord pattern in rats with hyperlipidaemia. It seemed like the hepatocytes, periportal area, and centrilobular part of the liver were all normal in the group who had the treatment. An analysis of the EZ plasma drug concentration with time was carried out in a research. The medication’s most effective concentration (Cmax) was determined to be within 4 h after delivery, and The quantified concentration of the active medication was detectable in the bloodstream for 24 h.ConclusionIn combination with piperine, EZ has demonstrated significant antioxidant and antihyperlipidemic effects. This indicates that EZ could be further utilised for treating hyperlipidemia and atherosclerosis due to its potential to boost the bioavailability and oral absorption of the drug.

A Delve into the Chemical Diversity, Pharmacological Targets, and Biological Mechanisms of Ichnocarpous frutescens Linn R. Br.: A Review on the Current Status of Knowledge

In India, Ichnocarpous frutescens Linn R. Br. (I. frutescens) is a woody climbing shrub belonging to the Apocynaceae family. Tribes traditionally use it as a substitute for Indian Sarsaparilla (Hemidesmus indicus) to treat conditions such as delirium, convulsions, atrophy, diarrhea, measles, splenomegaly, tuberculosis, tumours, and diabetes. It has also been used as a lactagogue, antipyretic, demulcent, diaphoretic, and skin moisturizer. This study aimed to gather information on the phytochemistry, traditional applications, and pharmacological properties of I. frutescens. Various scientific studies have evaluated their phytochemical components and therapeutic potential. Phytochemical studies have identified 28 compounds, including triterpenes, flavonoids, phytosterols, and other phenolic compounds. Several pharmacological effects of plant extracts have been documented, including anticancer, antiurolithiatic, hepatoprotective, antioxidant, analgesic, antipyretic, antiinflammatory, antidiabetic, and antihyperlipidemic activities. Additionally, this review examines the biological mechanisms underlying these pharmacological actions, emphasizing the potential therapeutic applications of the plant. By consolidating the current knowledge, this review serves as a valuable resource for further research and potential utilization of I. frutescens in modern pharmacotherapy, paving the way for future studies to explore its full range of effects and uses.

Kundur (Boswellia Serrata): Medicinal Importance in Perspective of Unani Medicine and Pharmacological Studies

Kundur, the Indian olibanum tree, is a member of the Burseraceae family and grows best in the dry mountainous regions of the Middle East, Northern Africa, and India. This tree has small to huge branches. The tree's oleo-gum resin is removed and stored from the incision created in its trunk. Resin makes roughly 30–60% of oleo-gum resin, with organic solvent-soluble essential oils making up the remaining 5–10%. Gum-resin extracts from Boswellia serrata have long been used in traditional medicine to treat a variety of chronic inflammatory diseases. Four primary pentacyclic triterpenic acids found in the resinous component of Boswellia serrata are β-boswellic acid, acetyl-β-boswellic acid, 11-keto-β-boswellic acid, and acetyl-11-keto-β-boswellic acid. This oleo-gum resin is quite popular among traditional practitioners of traditional Chinese and Indian Systems of medicine because of its wide range of useful biological properties such as anti-inflammatory, anti-arthritic, anti-rheumatic, anti-diarrheal, anti-hyperlipidemic, anti-asthmatic, anti-cancer, anti-microbial, anti-fungal, anti-complementary, and analgesic activity etc.

Murraya koenigii (L.) Spreng. as a Natural Intervention for Diabesity: A Review.

Murraya koenigii (L.) Spreng. (family: Rutaceae), commonly known as curry leaf or sweet neem, is a tropical plant native to India and Southeast Asia. It is highly valued in Ayurveda for its medicinal properties. Almost every part (fresh leaves, fruits, bark, and roots) of this plant is used to treat various ailments. Its fresh leaves are considered to have numerous medicinal properties for various diseases, including piles, inflammation, itching, fresh cuts, dysentery, and edema. A combination of curry leaf and buttermilk is used to treat diseases, such as amoebiasis, diabetes, and hepatitis. Its leaves are also believed to possess antioxidant, anti-inflammatory, and antimicrobial properties. The bark has been traditionally used for treating snakebites. Its roots are utilized in Ayurveda for the treatment of body aches. Being a storehouse of carbazole alkaloids, M. koenigii has been reported to show anti-obesity and anti-diabetic activity in in vitro and in vivo studies. The review aimed to appraise the role of M. koenigii leaf in the prevention of diabesity. We performed a literature search with the keywords "diabesity", "obesity", "diabetes", "adipose tissue", and "carbazole alkaloids" on Google Scholar, PubMed, and ScienceDirect databases. Several in vitro and in vivo studies conducted on cell lines and animals for anti-diabetic/anti-hyperglycemic and antihyperlipidemic activities have been included and appraised in the article, providing supporting evidence for the ethnomedicinal claims. This review has been an attempt to summarize comprehensively the overall research done on M. koenigii with regard to obesity and diabetes. The studies on anti-diabetic/anti-hyperglycemic and anti-hyperlipidemic activities of the plant have ranged from studies on crude extracts to isolated compounds. However, some of the studies require further in-depth analysis and validation of obtained results.

Hypoglycaemic, anti-hyperlipidemic, and anti-inflammatory activities of Asparagus africanus (Asparaceae) extract on high-fat diet/streptozotocin-induced diabetes in Wistar rats

Objective: To investigate the toxicity and effect of the extract on some complications of diabetes in Wistar rats. Methods: Type 2 diabetes was induced by a combination of a high-fat diet and streptozotocin (35 mg/kg, i.p.). Aqueous extract of Asparagus africanus (EAA) was prepared and administered (p.o.) for 28 d to groups of diabetic rats as well as to groups of normal rats for toxicity. Fasting blood glucose levels, inflammatory cytokines, and lipid profiles were assessed in diabetic rats. Body and organ weight as well as liver and kidney functions were examined to assess the sub-acute toxicity. Results: EAA for 28 d did not affect the body weight, the weight of the liver, kidney, and heart as well as the serum level of aspartate aminotransferase, alanine aminotransferase, urea, uric acid and creatinine in normal rats. In diabetic rats, the administration of EAA significantly lowered hyperglycemia, reduced interleukin (IL)-6, IL-1β, and tumour necrosis factor-α levels, and increased the level of IL-10. EAA also lowered cholesterol, triglyceride, and low-density lipoprotein cholesterol levels and augmented high-density lipoprotein cholesterol in the serum. As a result of the anti-lipidemic effect, EAA reduced the atherogenic index, Castelli indices, and atherogenic coefficient in diabetic rats. EAA showed the presence of flavonoids, alkaloids, tannins, saponins, terpenes, and steroids. Conclusions: The findings of this study demonstrated that EAA is safe. It has the potential to reduce the glucose level and the risk of inflammation and atherogenesis in diabetic patients.

Formulation and Evaluation of Anti-Hyperlipidemic Tablet

Hyperlipidemia is one of the leading causes of mortality in developed as well as in developing countries like India. It attributes to the high risk of coronary heart disease and atherosclerosis which is referred as a silent killer. Herbal treatment for hyperlipidemia is inexpensive, readily available locally, and has no negative side effects. Medicinal plants are the "backbone" of traditional medicine so considered as good source of life for all people due to its wealthy therapeutic properties and being 100% natural. Several drugs in Siddha have been found to be beneficial in lowering lipid levels without any major adverse effects. Numerous plants like arjuna, ashwagandha, garlic, guggul, etc. have been reported to have lipid-lowering effects. The goal of the review paper is to examine the potential anti-hyperlipidemic effects of herbal plants using a variety of models. The anti-hyperlipidemic activity of the most well-known medicinal herbs is the focus of this review.

Metabolite Profiling and Integrated Network Pharmacology Based Mechanism of Benincasa hispida (Thunb.) Cogn. Fruit Against Non-insulin-Dependent Diabetes Mellitus.

Benincasa hispida (Thunb.) Cogn. (Cucurbitaceae) is an essential food plant in India possessing antihyperglycemic and antihyperlipidemic activities. The objective included comparative estimation of α-glucosidase and α-amylase enzyme inhibition potential of B. hispida fractions prepared by microwave-assisted extraction and prediction of metabolite interaction against non-insulin-dependent diabetes mellitus by metabolite profiling based network pharmacology analysis. A validated microwave-assisted extraction method was employed to obtain different fractions of B. hispida fruits. The invitro enzyme assay was done with p-nitrophenyl-α-D-glucopyranoside and acarbose as standard to evaluate antidiabetic potential. The phytomolecules present in the active fraction wereidentified by UHPLC-QToF-MS/MS analysis. Network pharmacology analysis gave possible gene and disease association, combination synergy network, and predicted probable mechanism of action. The highest enzyme inhibition potential (IC50) was shown by the ethyl acetate fraction (0.546 ± 0.17 mg/mL and 1.134 ± 0.42 mg/mL) compared to acarbose (0.298 ± 0.08 mg/mL and 0.532 ± 0.38 mg/mL), respectively, for α-glucosidase and α-amylase addressing the potential role in ameliorating non-insulin-dependent diabetes mellitus. Metabolite profiling resulted in the identification of 17 metabolites, and a synergy between the identified molecules suggested multimolecule action in the amelioration of non-insulin-dependent diabetes mellitus through insulin resistance pathway, AMPK signaling pathway, PPAR signaling pathway, and PI3K-Akt signaling pathway. Combination synergy of identified molecules was observed through a multitarget approach to manage non-insulin-dependent diabetes mellitus. Polyphenol-enriched fraction of B. hispida fruits and identified phytocompounds ameliorate non-insulin-dependent diabetes mellitus. Thus, enriched extract of B. hispida can be further investigated in order to develop high-quality, safe, and effective products for the management of non-insulin-dependent diabetes mellitus.

Ganoderma lucidum triterpenoids investigating their role in medicinal applications and genomic protection.

Ganoderma lucidum (GL) is a white rot fungus widely used for its pharmacological properties and health benefits. GL consists of several biological components, including polysaccharides, sterols, and triterpenoids. Triterpenoids are often found in GL in the form of lanostane-type triterpenoids with quadrilateral carbon structures. The study revealed that triterpenoids have diverse biological properties and can be categorized based on their functional groups. Triterpenoids derived from GL have shown potential medicinal applications. They can disrupt the cell cycle by inhibiting β-catenin or protein kinase C activity, leading to anti-cancer, anti-inflammatory, and anti-diabetic effects. They can also reduce the production of inflammatory cytokines, thus mitigating inflammation. Additionally, triterpenoids have been found to enhance the immune system's defenses against various health conditions. They possess antioxidant, antiparasitic, anti-hyperlipidemic, and antimicrobial activities, making them suitable for pharmaceutical applications. Furthermore, triterpenoids are believed to afford radioprotection to DNA, protecting it from radiation damage. This review focuses on the types of triterpenoids isolated from GL, their synthesis pathways, and their chemical structures. Additionally, it highlights the pharmacological characteristics of triterpenoids derived from GL, emphasizing their significant role in various therapeutic applications and health benefits for both humans and animals.

Comprehensive Review on Nilofar (Nymphaea alba Linn): Unani Perspectives and Therapeutic Potentials

Nilofar (Nymphaea alba Linn) is commonly known as the white-water lily. It is a hydrophyte with enormous medicinal properties, renowned for its alluring white flowers. It is distributed worldwide in ponds, lakes, and marshy areas. Its various parts have been extensively utilized in Unani medicine globally, particularly in the Indian subcontinent, to prevent and treat a variety of ailments. Numerous research findings have documented its therapeutic effects, including anti-inflammatory, anti-hepatitis C, anti-diarrheal, hepatoprotective, antibacterial, anticarcinogenic, antiurolithiatic, uterotonic, anxiolytic, antidepressant, CNS depressant, anticonvulsant, antihyperlipidemic, and antioxidant activities. In Unani medicine, Nilofar is used to treat various illnesses such as palpitations, diarrhea, hepatotoxicity, inflammation, migraines, anxiety, depression, and convulsions. Nilofar contains a variety of chemical constituents, including alkaloids, tannins, flavonoids, phenolic content, glycosides, aglycons, phenolic acids, cardiac glycoside nymphalin, and others. This review explores the therapeutic potential of Nilofar, shedding light on its pharmacological properties, traditional uses, and emerging research. By combining traditional knowledge with the latest scientific findings, this review aims to encourage further research and facilitate its integration into mainstream healthcare practices.

Evaluation of the Hypoglycemic and Hypolipidemic Potential of Extract Fraction of Quercus baloot Griff Seeds in Alloxan-induced Diabetic Mice.

The discovery and development of new phytomedicines can be greatly aided by plants because of their tremendous therapeutic benefits, efficiency, cost-effectiveness, lack of side effects, and cheaper therapies. In this regard, Quercus baloot, generally known as oak, is used in folkloric medicine for treating and preventing various human disorders, including diabetes. For this purpose, the present study aimed to evaluate crude methanolic extract and various fractions of Quercus baloot for antihyperlipidemic and antihyperglycemic potential followed by the analysis of active compounds. The hypoglycemic and hypolipidemic activity was evaluated in Swiss male Albino mice by administering an oral dose of 150-300 mg/kg of Q. baloot extracts in alloxan induced diabetic mice for 14 days. The results revealed that crude methanolic extract at a dose of 300 mg/kg exhibited a significant reduction in the blood glucose level (198.50 ± 1.99 mg/dl) at day 14 and the same treatment significantly increased the body weight (31.26 ± 0.27 g) at day 14 in comparison to the control group. Moreover, the biochemical parameters were investigated which presented an increase in high-density lipids (HDL) (30.33 ± 0.33 mg/dl), whereas low-density lipids (LDL) showed a significant decrease (105.66 ± 0.26 mg/dl). Additionally, triglyceride levels 104.83 ± 0.70 mg/dl, and total cholesterol 185.50 ± 0.76 mg/dl are significantly decreased. In serum biochemical analysis creatinine and hepatic enzyme markers, like serum glutamate pyruvate transaminase (32.00 ± 0.36 U/mg), serum glutamate oxaloacetate transaminase (34.33 ± 0.61 U/mg), and alkaline phosphatase (157.00 ± 0.73 U/mg), were significantly reduced by the crude methanolic extract at a dose of 300 mg/kg as compared to the control group. The antioxidant enzymes like Superoxide dismutase (4.57 ± 0.011), peroxidases dismutase (6.53 ± 0.014, and catalase (8.38 ± 0.014) at a dosage of 300 mg/kg of methanolic extract exhibited a significant increase. The histopathological study of the diabetic heart, liver, and pancreas showed substantial restoration of damaged tissues in the methanolic extract 150 and 300 mg/kg treated group, which supports the effectiveness of Q. baloot seeds. The gas chromatography-mass spectrometry analysis of methanolic extract identified 10 antidiabetic active compounds in the Q. baloot seeds, validating the antihyperglycemic activity. Thus, methanolic crude extract at the doses 150 and 300 mg/kg of Q. baloot showed significant antihyperlipidemic and antihyperglycemic activities, which validate the folkloric utilization of Q. baloot as a remedy in diabetes. In conclusion, the 300 mg/kg methanolic extract of Q. baloot has notable hypoglycemic and hypolipidemic potential, supporting the plant's traditional medicinal usage in the treatment of diabetes and its complications. Further studies are needed for the purification, characterization, and structural clarification of bioactive compounds.

Antidiabetic and Antihyperlipidemic Activity of Ethanolic Extract of Mentha viridis in Alloxan Induced Diabetic Rats

This research was designed to examine the phytochemicals of Mentha viridis (M. viridis) ethanolic extract and the antidiabetic and antihyperlipidemic activities in alloxan-induced animal models. Diabetes was induced chemically by administering a unit dose of alloxan at 120 mg/kg BW. After alloxan induction, hyperglycemic rats were dealt with ethanolic extract of leaf and whole plant, metformin, and a mixture of leaf extract with metformin and whole plant extract with metformin for two weeks. Ethanolic extract of leaf and whole plant, metformin, and a combination of both leaf and whole plant extract with metformin therapies reduced glucose levels in the blood compared with the diabetic negative control group after two weeks of treatment. However, among the therapies, the ethanolic leaf extract and the combination of whole plant extracts with metformin were found to be the most effective (p&amp;lt;0.05), with reductions of 62.82% and 72.89%, respectively. After diabetes induction, the serum level of TG (triglycerides), TC (total cholesterol), LDL-C (low-density lipoprotein-cholesterol) escalated notably (p&amp;lt;0.05), and HDL-C (high-density lipoprotein-cholesterol) level decreased remarkably (p&amp;lt;0.05) in hyperglycemic rats as opposed to healthy normal rats. Ethanolic leaf extract and a combination of whole plant extract with metformin significantly minimized the elevated extent of TG and LDL-C. They surged HDL-C, but the TC level was reduced by whole plant extract only after two weeks of treatment. The standard procedures were used to identify the phytochemical compounds of the medicinal plant M. viridis. The phytochemical compounds such as alkaloids, resins, tannins, phenols, flavonoids, steroids, and terpenoids appeared in the ethanolic leaf extract of M. viridis. The findings suggest that M. viridis might provide better glycemic control and hypolipidemic effect in diabetic rats when administered alone or combined with oral antidiabetic agents. Incorporating M. viridis extract with metformin in improving hyperglycemic and hyperlipidemic conditions in diabetic rats proves that M. viridis has a synergistic effect, which could enhance the antidiabetic activity of oral hypoglycemic agents.

Impact of oil type on the development and oral bioavailability of self-nanoemulsifying drug delivery systems containing simvastatin

The aim of this work is to develop and evaluate self-nanoemulsifying drug delivery systems (SNEDDS) containing simvastatin to increase its oral bioavailability. Formulation EO 5 (Ethyl oleate 9.3% w/w: Tween 80 49.4% w/w: Propylene glycol 39.3% w/w) and Formulation CL 14 (Clove oil 54.3% w/w: Tween 80 34.4% w/w: Transcutol-P 9.3% w/w) were thoroughly studied. They showed emulsification time less than 1 min, droplet size in the nanometric range, and almost a complete drug release after 2 h. The in-vitro dissolution profile of both formulations was found to be significant in comparison to the pure drug in pH 1.2 and 7.4 buffers (P < 0.0001). Furthermore, they demonstrated superior anti-hyperlipidemic activity in comparison to simvastatin suspension (10 mg/kg/day). In order to investigate the impact of oil type on oral bioavailability, the selected formulations have been examined in terms of the in-vivo pharmacokinetic study, and formulation EO 5 was found to have higher bioavailability. After oral administration of a single dose (40 mg/kg) of simvastatin-loaded SNEDDS (CL14 and EO 5), a 1.5-fold and 1.95-fold increase in bioavailability were observed, respectively, as compared to simvastatin suspension. Hence, the results indicated that the developed SNEDDS could enhance the therapeutic efficacy and oral bioavailability of simvastatin.

An Approach to Development and In-vivo Evaluation of Beta Sitosterol Phytosomes by Taguchi Orthogonal Array Design.

The research mainly focused on developing and optimizing beta-sitosterol phytosomes through a systematic Taguchi orthogonal array design and assessment of their performance in both beta-sitosterol phytosomes. The fabrication of phytosomes containing β-sitosterol was carried out using the rotary evaporation technique. An orthogonal array design was employed in the study to precisely optimize the phytosomes. In this two responses and three independent variables were analyzed. The data was analyzed by using statistical modeling. Characterization of these phytosomes involves Fourier transform infrared spectroscopy, entrapment efficiency, differential scanning calorimetry compatibility study, zeta potential and particle size. Based on the findings, an optimized phytsome formulation was developed to achieve the best results. The results indicated that beta-sitosterol phytosomes responses are significant. It effectively reduced body weight as well as levels of total cholesterol (126.120 ± 0.98 mg/dl), triglycerides (104.23 ± 2.8 mg/dl), HDL (39.31 ± 0.45 mg/dl), VLDL (21.67 ± 0.34 mg/dl), and LDL (76.43 ± 0.34 mg/dl) in rats compared to the other groups. The orthogonal array design study observed that the anti-hyperlipidemic activity of β-sitosterol was nearly as potent as that achieved with standard drug therapy.

Antidiabetic and Antihyperlipidemic Activities and Molecular Mechanisms of Phyllanthus emblica L. Extract in Mice on a High-Fat Diet.

We planned to explore the protective activities of extract of Phyllanthus emblica L. (EPE) on insulin resistance and metabolic disorders including hyperlipidemia, visceral obesity, and renal dysfunction in high-fat diet (HFD)-progressed T2DM mice. Mice treatments included 7 weeks of HFD induction followed by EPE, fenofibrate (Feno), or metformin (Metf) treatment daily for another 4-week HFD in HFD-fed mice. Finally, we harvested blood to analyze some tests on circulating glycemia and blood lipid levels. Western blotting analysis was performed on target gene expressions in peripheral tissues. The present findings indicated that EPE treatment reversed the HFD-induced increases in blood glucose, glycosylated HbA1C, and insulin levels. Our findings proved that treatment with EPE in HFD mice effectively controls hyperglycemia and hyperinsulinemia. Our results showed that EPE reduced blood lipid levels, including a reduction in blood triglyceride (TG), total cholesterol (TC), and free fatty acid (FFA); moreover, EPE reduced blood leptin levels and enhanced adiponectin concentrations. EPE treatment in HFD mice reduced BUN and creatinine in both blood and urine and lowered albumin levels in urine; moreover, EPE decreased circulating concentrations of inflammatory NLR family pyrin domain containing 3 (NLRP3) and kidney injury molecule-1 (KIM-1). These results indicated that EPE displayed antihyperglycemic and antihyperlipidemic activities but alleviated renal dysfunction in HFD mice. The histology examinations indicated that EPE treatment decreased adipose hypertrophy and hepatic ballooning, thus contributing to amelioration of lipid accumulation. EPE treatment decreased visceral fat amounts and led to improved systemic insulin resistance. For target gene expression levels, EPE enhanced AMP-activated protein kinase (AMPK) phosphorylation expressions both in livers and skeletal muscles and elevated the muscular membrane glucose transporter 4 (GLUT4) expressions. Treatment with EPE reduced hepatic glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK) expressions to suppress glucose production in the livers and decreased phosphorylation of glycogen synthase kinase 3β (GSK3β) expressions to affect hepatic glycogen synthesis, thus convergently contributing to an antidiabetic effect and improving insulin resistance. The mechanism of the antihyperlipidemic activity of EPE involved a decrease in the hepatic phosphorylation of mammalian target of rapamycin complex C1 (mTORC1) and p70 S6 kinase 1 (S6K1) expressions to improve insulin resistance but also a reduction in hepatic sterol regulatory element binding protein (SREBP)-1c expressions, and suppression of ACC activity, thus resulting in the decreased fatty acid synthesis but elevated hepatic peroxisome proliferator-activated receptor (PPAR) α and SREBP-2 expressions, resulting in lowering TG and TC concentrations. Our results demonstrated that EPE improves insulin resistance and ameliorates hyperlipidemia in HFD mice.

Adenocalymma alliaceum: An Overview

Adenocalymma alliaceum, commonly known as Garlic Vine or Lahsun bel, is an herbal shrub belonging to the family Bignoniaceae. It is native to northern Brazil and the Amazon rainforest, and certain species can also be found in the Chhattisgarh, Kerala states of India. This evergreen plant is highly valued for its ornamental qualities, with bright green leaves and tri-colored blooms that emit a distinct garlic-like fragrance. It grows up to 6-8 feet in height and is popular for landscaping purposes. The plant has various pharmacological activities that have been studied particularly in the management of diabetes mellitus. The bark, leaves, stems, and roots of Adenocalymma alliaceum contain a range of bioactive compounds that have been used to treat different diseases and disorders. Phytoconstituents such as diallyl disulfide and diallyl trisulfide are major chemical constituents of the plant, exhibiting antimicrobial, antihyperlipidemic, antifungal, and antimycotic activities. These properties make Adenocalymma alliaceum a promising source for the development of allopathic drugs. While the plant has traditional and cultural significance, it has also gained attention for its potential therapeutic properties. However, it is important to note that although it is used as a folk medicine in local communities, it is not extensively mentioned in published books or literature. In summary, Adenocalymma alliaceum is an intriguing natural resource with a rich cultural heritage and significant pharmacological potential. Further research and exploration of this plant may uncover additional therapeutic benefits and contribute to the development of novel drugs and treatments.

Evaluation of Anti-Hyperlipidemic Activity of the Seeds Extracts of Ficus carica: In Vitro and In Silico Approaches.

Obesity and hyperlipidemia have become major disorders predominantly causing prevailing cardiovascular diseases and ultimately death. The prolonged use of anti-obesity drugs and statins for reducing obesity and blood lipid levels is leading toward adverse effects of kidneys and muscles, specifically rhabdomyolysis. The objective of this study is to evaluate potential of seeds of Ficus carica against hyperlipidemia. Various extracts and isolated compounds from fig seeds were analyzed and evaluated for their anti-hyperlipidemic potential. Methanol extract and its ethyl acetate fraction showed maximum pancreatic lipase inhibition of 61.93% and 86.45% in comparison to reference drug Orlistat. Four compounds isolated by HPLC-PDA technique were determined as Gallic acid, Catechin, Epicatechin, and Quercetin also showed strong potential to inhibit enzyme pancreatic lipase comparable to Orlistat. These isolated compounds were further analyzed for molecular docking and MM-GBSA studies. Three ligands, namely Quercetin, Epicatechin, and Catechin were found more effective against pancreatic lipase as these possessed docking scores (-9.881, -9.741, -9.410) higher to that of the reference ligand Orlistat (-5.273). The binding free energies of these compounds were -55.03, -56.54, and 60.35 kcal/mol, respectively. The results have shown that Quercetin has the highest binding affinity correlating with the highest inhibition of pancreatic lipase enzyme 1LPB. Hence, it is suggested that seeds of F. carica have promising anti-hyperlipidemic potential and foremost in reducing obesity.

Lipid-Lowering and Anti-Inflammatory Effects of Campomanesia adamantium Leaves in Adipocytes and Caenorhabditis elegans.

Obesity is a pandemic disease characterized by lipid accumulation, increased proinflammatory cytokines, and reactive oxygen species. It is associated with the development of comorbidities that lead to death. Additionally, drug treatments developed to control obesity are insufficient and have a variety of adverse effects. Thus, the search for new anti-obesity therapies is necessary. Campomanesia adamantium is a species from the Brazilian Cerrado that has the potential to treat obesity, as described by the antihyperlipidemic activity of its roots. Therefore, this study aimed to investigate the activity of the aqueous extract of C. adamantium leaves (AECa) on the control of reactive species in vitro, on lipid accumulation in adipocytes and Caenorhabditis elegans, and on the production of proinflammatory cytokines in adipocytes. The antioxidant capacity of AECa was observed by its action in scavenging DPPH• free radical, iron-reducing power, and inhibition of β-carotene bleaching. AECa reduced lipid accumulation in preadipocytes and in C. elegans. Moreover, AECa reduced the production of the proinflammatory cytokines MCP-1, TNF-α, and IL-6 in adipocytes. In summary, the antioxidant activity and the ability of AECa to reduce the accumulation of lipids and proinflammatory cytokines indicate, for the first time, the anti-obesity potential of C. adamantium leaves.

Virgin Coconut Oil-based Nanostructured Lipid Carrier Improves the Hypolipidemic Effect of Rosuvastatin.

Monitoring noncommunicable diseases is regarded as a critical concern that has to be managed in order to avoid a wide variety of complications such as increasing blood lipid levels known as dyslipidemia. Statin drugs, mostly, Rosuvastatin (RSV) was investigated for its effectiveness in treating dyslipidemia. However, reaching the most efficient treatment is essential and improving the effect of RSV is crucial. Therefore, a combination therapy was a good approach for achieving significant benefit. Although RSV is hydrophobic, which would affect its absorption and bioavailability following oral administration, overcoming this obstacle was important. To that end, the purpose of the present investigation was to incorporate RSV into certain lipid-based nanocarriers, namely, nanostructured lipid carrier (NLC) prepared with virgin coconut oil (CCO). The optimized RSV-NLC formula was selected, characterized and examined for its in vitro, kinetic, and stability profiles. Eventually, the formula was investigated for its in vivo hypolipidemic action. The optimized NLC formulation showed a suitable particle size (279.3±5.03 nm) with PDI 0.237 and displayed good entrapment efficiency (75.6±1.9%). Regarding in vitro release, it was efficiently prolonged for 24 h providing 93.7±1.47%. The optimized formula was established to be stable after 3 months storage at two different conditions; 4°C and 25°C. Importantly, including CCO in the development of RSV-NLC could impressively enhance lowering total cholesterol level in obese rat models, which endorse the potential synergistic action between RSV and CCO. The study could elucidate the impact of developing NLC using CCO for improving RSV anti-hyperlipidemic activity.

ANTI-HYPERLIPIDEMIA ACTIVITY IN THE VIVO TEST FROM A COMBINATION OF AVOCADO LEAF EXTRACT (Persea americana Mill) AND GINGER RHIZOME (Curcuma xanthorrhiza Roxb) IN MICE WITH HYPERCHOLESTEROLEMIA

Herbal and traditional medicine are two of the main types of treatment in developing countries, including Indonesia. Hyperlipidemia is a condition in which cholesterol levels in the body exceed normal limits, impacting cardiovascular disease. Avocado leaves and temulawak rhizomes have been shown to have antihyperlipidemic effects in animals. This study aimed to determine the anti-hyperlipidemic activity of avocado leaf (Persea americana Mill) and temulawak rhizome (Curcuma xanthorrhiza Roxb) combination extract in cholesterol levels of white male mice Sprague Dawley strain. The subjects of this study consisted of 20 white male mice Sprague Dawley strain (Rattus novergicus) and were divided into five groups: F1 (standard); F2 (hypercholesterolemic group); F3 (1:1 treatment group); F4 (1:2 treatment group); and F5 (2:1 treatment group). The induction was conducted for 14 days, while the treatment was carried out for seven days. All data were analyzed using the Kruskal-Wallis and Mann-Whitney tests. The combination extract of avocado and temulawak rhizome has an anti-hyperlipidemic activity. Giving a combination extract of avocado leaf and temulawak rhizome to all treatment groups significantly reduced total cholesterol levels in mice (p = 0.028). Avocado leaves and temulawak rhizomes have potential antihyperlipidemic activity derived from flavonoids. In this study, the potency of the extract efficacy can be achieved when given in combination.